Background {#Sec1}
==========

Recent evidence confirms that exercise training provides myriad benefits for individuals with cystic fibrosis (CF) \[[@CR1]--[@CR4]\]. However, the mode (e.g., aerobic, strength, inspiratory muscle or some combination thereof), frequency, duration and intensity of training to optimise benefit have yet to be clarified \[[@CR5]\]. In addition to differences related to subject characteristics (e.g., age, sex, nutritional status, degree of pulmonary impairment and/or inflammation/infection status) \[[@CR6]\], this ambiguity likely reflects the fact that different outcome measures have been used to quantify exercise's beneficial effects. Interestingly, in addition to pulmonary function (e.g., FEV~1~) and health-related quality-of-life estimates, the peak rate of oxygen (O~2~) uptake (V̇O~2~) achieved on a maximal incremental exercise test (V̇O~2peak~) has been routinely used to quantify 'functional capacity' \[[@CR3], [@CR7]--[@CR10]\] for individuals with CF. However, while inversely related to hospitlalzation \[[@CR11]\] and mortality \[[@CR12]\], the degree to which V̇O~2peak~ reflects the capacity for satisfying the demands of everyday function for these individuals has been questioned \[[@CR13]\]. Instead, the capacity to rapidly adjust V̇O~2~ in response to submaximal energetic transitions like those encountered on a daily basis (i.e., 'V̇O~2~ kinetics') might provide a better indication of functional capacity for these individuals \[[@CR13]\]. Faster V̇O~2~ kinetics minimises the size of the 'O~2~ deficit' thereby reducing substrate-level phosphorylation and improving the ability to tolerate physical exertion \[[@CR14]\]. This has resonance for individuals with CF who typically demonstrate low tolerance for physical activity \[[@CR15]--[@CR17]\]. It is, therefore, not surprising that a strong correlation exists between the V̇O~2~ time constant (a parameter that quantifies the rapidity of the V̇O~2~ response) and disease severity in subjects with CF \[[@CR18]\]. With this in mind, it stands to reason that a training program that improves the capacity to rapidly adjust V̇O~2~ in response to lower-intensity energetic transitions like those encountered on a daily basis would likely have clinical implications \[[@CR13]\]. An improved ability to sustain higher-intensity exercise (i.e., work performed at a work rate that exceeds those that are associated with physical activity performed during daily living) might also have implications for pulmonary patients with respect to health-related quality of life and physical-activity levels \[[@CR19]\].

The exercise intolerance demonstrated by individuals with CF is multifactorial with mechanistic bases that shift as the individual ages and the severity of the disease increases \[[@CR20]\]. With respect to oxidative capacity, limiting factors can include an impaired ability to deliver O~2~ to skeletal muscle due to a disease-related decline in pulmonary \[[@CR20]--[@CR22]\] and/or cardiac \[[@CR23]\] function (central limitation) and/or a reduced capacity for skeletal-muscle mitochondria to extract/use O~2~ that is delivered (peripheral limitation) \[[@CR13], [@CR24], [@CR25]\]. A slower V̇O~2~ response has been observed for CF subjects \[[@CR13], [@CR18], [@CR25], [@CR26]\] with the decrement found to be mechanistically linked to impaired muscle extraction and utilization \[[@CR13]\]. If an O~2~-utilization limitation to V̇O~2~ kinetics is responsible for the reduced tolerance to exercise displayed by individuals with CF, exercise training to improve mitochondrial function might be particularly important for these individuals.

Recent research confirms that high-intensity interval training (i.e., periods of high-intensity 'work' intervals interspersed with recovery intervals of low-intensity exercise or rest; HIIT) provides a potent stimulus for enhancing mitochondrial function \[[@CR27]\] and HIIT has proven both safe and effective for improving exercise capacity for individuals with CF \[[@CR28]\]. Collectively, this implies that HIIT might be an ideal approach for improving functional capacity in these individuals. However, it stands to reason that to provide maximal peripheral stimulation of muscle mitochondria with HIIT, it is necessary to circumvent any central limitation in pulmonary and/or cardiovascular function that might concurrently be in effect. Oxygen supplementation has proven effective for reducing O~2~ desaturation and decreasing ventilatory and cardiovascular work for CF subjects during incremental maximal \[[@CR29], [@CR30]\] and constant-work-rate (CWR) submaximal exercise \[[@CR29], [@CR31]\]. Furthermore, hyperoxic inspiration would help to counter the hypoxia associated with high-intensity exercise that influences O~2~-mediated signaling cascades (e.g., HIF1α) which affect the adaptive response to training. Collectively, these alterations consequent to hyperoxic inspiration raise the intriguing possibility that a training regimen involving HIIT performed in conjunction with O~2~ supplementation might be more effective for improving maximal and submaximal exercise capacity in CF subjects compared to HIIT while breathing ambient air.

The main purpose of this study was to assess the beneficial effects of an eight-week HIIT cycling intervention for individuals with CF. Specifically, we made pre-/post-training comparisons for: 1.) the ability of oxidative metabolism to adapt to an increase in external work performed (as indicated by the V̇O~2~ mean response time; MRT); and 2.) the ability to sustain exhaustive exercise (as indicated by the time to limit of tolerance; T~lim~). We hypothesized that: 1.) HIIT would reduce the V̇O~2~ MRT during lower-intensity CWR exercise; 2.) HIIT would increase the time to limit of tolerance during higher-intensity CWR exercise.

Methods {#Sec2}
=======

This study employed a randomized, single-blind design. Participants were randomly assigned to a group performing HIIT with O~2~ supplementation (O2+; *n* = 6) or a group performing HIIT while breathing ambient air (AMB; *n* = 5). Participants blinded to the treatment performed HIIT on a cycle ergometer 2 days per week for 8 weeks. Each exercise session was \~ 45 min in duration. This volume (e.g., weeks of training completed and duration of training sessions) was chosen based on our observations regarding what represents a reasonable time investment for this type of individual. Participants fasted for 4 h and abstained from alcohol for 24 h prior to each exercise session. They also refrained from performing strenuous physical activity for 24 h prior to each visit.

Participants visited the Cardiovascular Research Unit at Dublin City University on three separate days before and after the training program. Each visit was separated by ≥72 h. During these visits, participants performed the pre- and post-training evaluations while in stable health and while not receiving antibiotics or other medications. During the first visit, anthropometric measurements were taken, spirometry and single-breath carbon monoxide diffusion capacity (DLCO) were determined and V̇O~2peak~ and peak rate of minute ventilation (V̇~Epeak~) were measured during an incremental cycling bout. During the second and third visits, participants performed CWR cycling bouts at 30% (CWR~30~) and 70% (CWR~70~) of the peak work rate achieved on the incremental test.

Subjects {#Sec3}
--------

Eleven CF subjects (male, *n* = 6) were recruited to take part in this study. The subjects were recruited from the pulmonary department of a local hospital. All patients had documented and proven CF as indicated by clinical characteristics and identified cystic fibrosis transmembrane conductance regulator (CFTR) alteration mutation and/or pathological sweat chloride test (\>60 mmol∙L^− 1^). Participants were eligible for inclusion if they possessed no other diseases that could limit their exercise capacity. Participants were excluded from the study if their forced expiratory volume in 1 s (FEV~1~) was less than 30% of the predicted value and they were not clinically stable. The nature and risks of the study were explained. A plain language statement was read and written informed consent was obtained in accordance with the Hospital Medical Ethics Committee. This research was approved by the Ethics (Medical Research) Committee at Beaumont Hospital in Dublin (\#07/83).

Anthropometric measurements {#Sec4}
---------------------------

Height and body mass were measured and double thickness subcutaneous adipose tissue was determined on the right side of the body using a skinfold caliper (Harpenden, Cambridge Scientific Industries, MD, USA). Percent body fat was calculated based on the equation proposed by Jackson and Pollock \[[@CR32]\].

Pulmonary-function tests {#Sec5}
------------------------

Standard pulmonary-function tests including spirometry and measurements of DLCO (Sensormedics Vmax 229, Sensormedics Corp, CA, USA) were undertaken and results were compared to normative values \[[@CR33], [@CR34]\]. Predicted maximal voluntary ventilation (MVV) was calculated by multiplying FEV~1~ by 40 \[[@CR35]\].

Incremental cycling test {#Sec6}
------------------------

Participants performed an incremental symptom-limited peak exercise test on an electronically-braked cycle ergometer (Ergoselect 100, Ergoline GmbH) while breathing through a full face mask. Prior to work-rate incrementation, 3 min of gas-exchange data were collected both at rest and during 'unloaded' cycling. Importantly, these incremental tests were individualised by setting the rate of incrementation in accordance with the disease severity and fitness level of the participant. For example, if FEV~1~ was less than 40% of the predicted value, an incrementation rate of 5 W∙min^− 1^ was employed. When FEV~1~ fell between 40 and 60% of the predicted value, incrementation was 10 W∙min^− 1^ and for values above 60%, a rate of 10--25 W∙min^− 1^ was used. The goal was to have participants reach their limit of exercise tolerance within 8--12 min. The V̇O~2peak~ was defined as the highest 30-s rolling-average value present during the test. Criteria for maximal effort or symptom limitation on the exercise test were RER \>1.15 and/or BR \<11 l^.^min^− 1^. Dyspnea and leg fatigue were scored on a Borg scale (0--10) every minute during exercise.

Constant-work-rate cycling tests {#Sec7}
--------------------------------

Participants performed two CWR cycling bouts on the same ergometer that was used for the incremental test. These bouts were separated by 2--3 days. As previously mentioned, the work rates for these bouts were set at a percentage of the peak work rate that was achieved on the incremental test; specifically, 30 and 70% for CWR~30~ and CWR~70~, respectively. Hence, these constant-work-rate tests were individualised for each participant based on their ability to perform incremental work at a maximal level. Participants performed CWR~30~ for 10 min to provide an adequate amount of time to determine V̇O~2~ kinetics whereas CWR~70~ was continued for 30 min or until limit of tolerance if it occurred prior to assess exercise endurance. Both bouts were preceded by 10 min of unloaded cycling. Gas-exchange, heart rate (HR) and peripheral capillary O~2~ saturation (SpO~2~) data were continuously collected and end-exercise values were defined as the average of values collected during the final 30 s of the bouts. Dyspnea and leg fatigue were assessed (see above) every 5 min.

Open-circuit Spirometry {#Sec8}
-----------------------

Expired O~2~ and carbon dioxide (CO~2~) concentrations and ventilatory volumes were measured breath by breath using open-circuit spirometry (Innocor, Innovision, Denmark). Airflow was measured by pneumotach using a differential pressure transducer (Innocor, Innovision, Denmark). Gases were sampled at a rate of 120 ml∙min^− 1^ and analysed by photoacoustic spectroscopy. The system was calibrated according to the manufacturer's procedures using a 3-L syringe (Series 5530, Hans Rudolph Inc., Germany). A 12-lead ECG (Case 8000, Marquette GE, USA) was used to measure HR while pulse oximetry (Nonin 8500, Nonin Medical, INC, NH, USA) was used to measure SpO~2~. Blood samples were taken from an earlobe every minute during each of the three exercise tests and these samples were used to determine blood-lactate concentration (\[lactate\]) (Accu Check Softclix Pro Lancet, Accu Check, Australia).

Quantification of V̇O~2~ kinetics {#Sec9}
--------------------------------

Breath-by-breath V̇O~2~ data from each CWR bout were initially examined to exclude errant breaths caused by coughing, swallowing, sighing, etc., and those values lying more than 4 SDs from the local mean were considered for removal. The breath-by-breath data were subsequently fit with an exponential curve to provide information regarding V̇O~2~ kinetics. We used a single exponential model without time delay with fitting window commencing at *t* = 0 s (i.e., the point at which the square-wave transition to the constant exercise work rate was made) to derive the MRT for the V̇O~2~ response. Specifically, we used a nonlinear least-squares algorithm as described in the following equation to fit the data:
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where V̇O~2~ (*t*) is the absolute V̇O~2~ at a given time *t*, V̇O~2base~ represents the mean V̇O~2~ during the final 30 s of baseline cycling, A represents the amplitude of the response and MRT indicates the time that will be required for the response to reach \~ 63% of completion with no distinction made for the various phases of the response. An iterative process was used to minimise the sum of the squared errors between the fitted function and the observed values. We also determined the V̇O~2~ at minutes 3 and 6 of both CWR bouts so that we could calculate the increase in V̇O~2~ that occurred between these two time points and between minute 3 and exhaustion for CWR~70~. In lieu of modeling the various phases of the response, this index has been used to estimate the amplitude of the V̇O~2~ slow component that is present for CWR exercise above the lactate threshold \[[@CR36]\].

High-intensity interval training program {#Sec10}
----------------------------------------

Each HIIT session involved work intervals performed at 70% of the peak work rate achieved on the incremental test followed by 60 s of recovery cycling at 35%. The overarching objective over the course of the eight-week intervention was to gradually increase the duration of the work intervals with the duration of the recovery intervals held constant. The increase was determined according to participant tolerance under the guidance of a therapist based on the ratings of leg fatigue and dyspnea. Each training session was limited to 45 min so when work-interval duration was increased in this manner, participants performed less repetitions. Each HIIT session comprised 5 min of warm-up cycling at 5--10 W followed by the work/recovery HIIT sequence. A five-minute active recovery period was allowed following the HIIT session. The first session was used to familiarize participants with the training protocol. During this familiarization session, subjects were limited to ≤15 min of performance of the high-intensity work intervals. As was the case with the incremental test (see above), throughout these training sessions, HR and SPO~2~% were measured continuously, blood \[lactate\] was assessed and dyspnea and leg-fatigue scores were monitored.

Oxygen supplementation {#Sec11}
----------------------

During each HIIT training session, participants wore a nasal cannula through which either medical oxygen (100%) or ambient air was delivered continuously at 3 L∙min^− 1^. The former comprised the experimental condition (O2+) while the later represented the placebo treatment (AMB).

Statistical analysis {#Sec12}
--------------------

Data are presented as mean ± SD. Between-group comparisons for baseline measurements were compared using an independent t-test. Changes in the physiological responses at peak exercise, upon completion of CWR~30~ and at the 'isotime' (i.e., completion time of the pre-training bout) for CWR~70~ were compared using time (pre-, post-training) x condition (O2+, AMB) repeated-measure analysis of variance. When a significant main effect was found, we examined estimated marginal means to determine its location. Statistical significance was accepted when *P* \< 0.05. Data were analysed using SPSS v17.0 (SPSS Inc., IL).

Results {#Sec13}
=======

A CONSORT diagram outlining the flow of subjects through the stages of the present investigation is provided in Fig. [1](#Fig1){ref-type="fig"} and individual-subject anthropometric, pulmonary-function and incremental-test data at baseline are presented in Table [1](#Tab1){ref-type="table"}. Two of the 11 recruited subjects (one from each group) did not complete the study. One subject was excluded due to low compliance with the training program and the other was excluded due to an abnormal ECG response. Training sessions had to be rescheduled for three subjects (O2+; *n* = 2) due to exacerbation of their CF diseased state. Three subjects in O2+ and three subjects in AMB were 'respiratory limited' by a low breathing reserve during the baseline incremental testing. Fig. 1CONSORT diagram outlining the flow of subjects through the stages of the present investigation Table 1Pre-training anthropometric, pulmonary-function and incremental-test data for the O2+ and AMB groupsO2+AMB*P*Age (y)29 ± 727 ± 40.715Height (cm)169 ± 6170 ± 100.894Body mass (kg)59 ± 764 ± 180.528Lean body mass (kg)50 ± 451 ± 150.845FEV~1~ (% predicted)58 ± 2557 ± 360.943FVC (% predicted)84 ± 1671 ± 300.456DLCO (% predicted)78 ± 1283 ± 240.703WR~peak~ (W)117 ± 59121 ± 710.927V̇O~2peak~ (ml∙min^−1^)1.60 ± 0.551.64 ± 0.710.921V̇~Epeak~ (L∙min^−1^)71 ± 2763 ± 290.648*FEV*~*1*~ Forced expiratory volume in 1 s, *FVC* Forced vital capacity, *DLCO* Diffusing capacity for carbon monoxide, *WR*~*peak*~ peak rate of work achieved on incremental cycling test, *V̇O*~*2peak*~ peak rate of oxygen uptake achieved on incremental cycling test, *V̇*~*Epeak*~ peak rate of minute ventilation achieved on incremental cycling test

Pre-/post-training comparisons {#Sec14}
------------------------------

### Anthropometric and pulmonary-function measurements {#Sec15}

There was no significant difference in body mass (*P* = 0.835) or lean body mass (*P* = 0.108) post compared to pre training in either group. However, a main effect of time was present for body-fat percentage (*P* = 0.021), which increased during the training intervention (O2+: pre, 21.1 ± 3.5%; post, 22.4 ± 3.8%; AMB: pre, 15.2 ± 6.7%; post, 15.9 ± 6.8%). There were no pre/post differences for any of the pulmonary-function measurements that were made (*P* \> 0.05).

### Incremental cycling test {#Sec16}

The physiological responses during the incremental cycling test pre and post training are provided in Table [2](#Tab2){ref-type="table"}. A main effect of time was observed for SpO~2~% (*P* \< 0.05); however, no significant pre/post differences were observed for V̇O~2peak~ or peak HR for either group. Table 2Pre-/post-training measurements during the incremental cycling test to the limit of tolerance for the O2+ and AMB groupsO2+AMBTimeGroup\
x\
TimePrePostPrePost*PP*V̇O~2peak~ (ml^.^kg^− 1^LBM^.^min^− 1^)32 ± 1134 ± 1132 ± 534 ± 110.3870.963WR~peak~ (W)117 ± 59131 ± 70121 ± 71137 ± 1010.0800.883HR~peak~ (beats^.^min^− 1^)167 ± 19166 ± 19159 ± 30158 ± 220.8660.929Peak RER1.1 ± 0.11.1 ± 0.01.1 ± 0.11.1 ± 0.10.9330.783V̇~Epeak~ (L^.^min^− 1^)71 ± 2772 ± 3663 ± 2961 ± 280.8420.694V~Tpeak~ (L)1.6 ± 0.81.5 ± 0.91.6 ± 0.91.7 ± 1.30.7570.672Peak BR (breaths^.^min^− 1^)49 ± 949 ± 944 ± 1243 ± 130.9080.706Peak SpO~2~%93 ± 490 ± 7\*93 ± 691 ± 5\*0.0210.240Peak \[Lactate\] (mmol^.^ L^− 1^)6.2 ± 1.86.3 ± 2.56.4 ± 3.26.1 ± 2.20.7620.704Peak RPE15.4 ± 2.515.6 ± 3.116.0 ± 1.416.5 ± 1.00.4070.717Peak dyspnea6.6 ± 2.16.2 ± 2.46.0 ± 1.86.3 ± 1.00.8790.515Values are presented as mean ± SD. *V̇O*~*2peak*~ peak rate of oxygen uptake, *RER* Respiratory exchange ratio, *V̇*~*Epeak*~ peak rate of minute ventilation, *V*~*Tpeak*~ peak tidal volume, *BR* Breathing rate, *SpO*~*2*~ peripheral capillary O~2~ saturation, *\[lactate\]* blood lactate concentration, *RPE* Rating of perceived exertion, \* = significantly different from pre-training value within group (*P* \< 0.05)

### Constant-work-rate tests {#Sec17}

The pre-/post-training measurements for constant-work-rate tests are presented in Table [3](#Tab3){ref-type="table"} (CWR~30~) and Table [4](#Tab4){ref-type="table"} (CWR~70~) and representative-subject data is provided in Fig. [2](#Fig2){ref-type="fig"}. For CWR~30~, a main effect of time was observed for the V̇O~2~ MRT (*P* = 0.000) indicating that HIIT accelerated low-intensity V̇O~2~ kinetics for these subjects. A main effect of time was also present for end blood \[lactate\] during CWR~30~ (*P* = 0.018) with a significant group-by-time interaction indicating that this was the case for O2+ (*P* = 0.009). During CWR~70~, HIIT increased time to limit of tolerance (*P* = 0.002) and decreased the blood \[lactate\] response (*P* = 0.003) with no group-by-time interaction observed for either variable (*P* = 0.143 and *P* = 0.102, respectively). Conversely, the V̇O~2~ MRT was unaltered by HIIT at the higher intensity of work (*P* = 0.168) although it was reduced in six of the nine subjects that were tested. At isotime, V̇~E~ and BR decreased with a significant group-by-time interaction indicating that this was the case for O2+ (*P* \< 0.05). Table 3Pre-/post-training measurements during 10-min constant-work-rate test at 30% of peak work rate for O2+ and AMB groupsO2+AMBTimeGroup\
x\
TimePrePostPrePost*PP*Baseline V̇O~2~ (L^.^min^− 1^)0.39 ± 0.060.40 ± 0.060.32 ± 0.080.36 ± 0.120.1520.262V̇O~2~ MRT (s)44 ± 934 ± 1145 ± 1739 ± 140.000\*0.130V̇O~2~ amplitude (L^.^min^− 1^)0.54 ± 0.190.52 ± 0.210.59 ± 0.200.57 ± 0.240.3910.968∆V̇O~2\ (6-3)~ (L^.^min^− 1^)0.01 ± 0.060.03 ± 0.040.00 ± 0.030.04 ± 0.030.1480.655End V̇~E~ (L^.^min^− 1^)32 ± 228 ± 529 ± 330 ± 40.1190.024\*End V~T~ (L)1.1 ± 0.51.1 ± 0.51.2 ± 0.51.1 ± 0.60.1220.110End BR (br^.^min^− 1^)35 ± 1130 ± 931 ± 1331 ± 120.1860.119End SpO~2~%94 ± 294 ± 295 ± 394 ± 30.4070.079End \[lactate\] (mmol^.^ L^− 1^)2.9 ± 0.81.5 ± 0.31.6 ± 0.21.7 ± 0.60.018\*0.009\*End RPE11.0 ± 1.49.8 ± 1.310.0 ± 2.910.8 ± 2.60.7540.200End dyspnea2.2 ± 1.31.6 ± 1.52.3 ± 1.02.3 ± 1.70.4610.461Values are presented as mean ± SD. *MRT* Mean response time, *∆V̇O*~*2\ (6-3)*~ change in V̇O~2~ from minute 3 to 6, V̇~E~, rate of minute ventilation, *V*~*T*~ tidal volume, *BR* Breathing rate, *SpO*~*2*~ peripheral capillary O~2~ saturation, *\[lactate\]* blood lactate concentration, *RPE* Rating of perceived exertion; \* *P* \< 0.05 Table 4Pre-/post-training measurements during constant-work-rate test at 70% of peak work rate for O2+ and AMB groupsO2+AMBTimeGroup\
x\
TimePrePostPrePost*PP*Baseline V̇O~2~ (L^.^min^− 1^)0.40 ± 0.070.41 ± 0.080.37 ± 0.060.37 ± 0.100.8640.924V̇O~2~ MRT (s)61 ± 651 ± 1464 ± 1858 ± 290.1680.699V̇O~2~ amplitude (L^.^min^− 1^)1.03 ± 0.410.99 ± 0.441.09 ± 0.581.06 ± 0.590.2110.830∆V̇O~2\ (6-3)~ (L^.^min^− 1^)0.11 ± 0.070.14 ± 0.140.11 ± 0.070.05 ± 0.080.6250.068Isotime V̇~E~ (L^.^min^− 1^)58 ± 1748 ± 1246 ± 845 ± 100.006\*0.026\*Isotime V~T~ (L)1.5 ± 0.71.4 ± 0.61.6 ± 0.91.5 ± 0.90.0540.281Isotime BR (br^.^min^− 1^)42 ± 836 ± 736 ± 1437 ± 160.041\*0.006\*Isotime SpO~2~%90 ± 691 ± 490 ± 989 ± 70.6680.413Isotime \[lactate\] (mmol^.^ L^− 1^)6.3 ± 1.44.5 ± 0.95.2 ± 1.44.5 ± 0.60.003\*0.102Isotime RPE14.4 ± 1.911.8 ± 1.813.8 ± 1.514.8 ± 2.90.2130.018\*Isotime dyspnea5.0 ± 1.94.0 ± 1.04.0 ± 1.24.5 ± 1.70.6010.145Limit of tolerance (min)11 ± 225 ± 612 ± 618 ± 110.002\*0.143Values are presented as mean ± SD. *MRT* Mean response time, *∆V̇O*~*2\ (6-3)*~ change in V̇O~2~ from minute 3 to 6, V̇~E~, rate of minute ventilation, *V*~*T*~ Tidal volume, *BR* Breathing rate, *SpO*~*2*~ peripheral capillary O~2~ saturation saturation, *\[lactate\]* blood lactate concentration, *RPE* Rating of perceived exertion; \* *P* \< 0.05 Fig. 2Rate of pulmonary oxygen uptake for a representative subject in the O2+ group before (top panel) and after (bottom panel) an eight-week training intervention comprising HIIT performed twice per week. The data were collected during unloaded cycling (time = − 60 to 0 s) followed by a square-wave increase to 30% of the subject's peak work rate. Closed circles depict 5-s averages of breath-by-breath V̇O~2~ data while solid line depicts modelled fit. Notice the marked reduction in the V̇O~2~ MRT (i.e., the time taken for V̇O~2~ to reach \~ 63% of the steady-state amplitude) and consequent reduction in the O~2~ deficit indicated by the dashed line (O~2~ deficit = MRT x Amplitude)

### High-intensity interval training {#Sec18}

The work rates for the work (O2+, 82 ± 42 W; AMB, 85 ± 50 W) and recovery (O2+, 41 ± 21 W; AMB, 42 ± 25 W) intervals were not significantly different between groups (*P* = 0.927). Over the course of the eight-week training intervention, both groups experienced a significant increase in work-interval duration during training sessions (*P* = 0.000); however, the change in O2+ was significantly greater than the change in AMB (*P* = 0.027; Fig. [3](#Fig3){ref-type="fig"}). Data exemplifying this progression for a representative subject in each group over the course of the intervention is provided in Table [5](#Tab5){ref-type="table"}. Both groups also demonstrated a decreased blood \[lactate\] response during the final high-intensity interval of the sessions of week eight compared to week one (*P* = 0.014); however, in this case, there was no group-by-time interaction (O2+: pre, 4.3 ± 1.7 mmol^.^ L^− 1^; post, 3.0 ± 0.9 mmol^.^ L^− 1^; AMB: pre, 3.2 ± 0.2 mmol^.^ L^− 1^; post, 2.6 ± 0.5 mmol^.^ L^− 1^). Average SpO~2~% during the final 15 s of the final work interval during the training sessions ranged from 92 to 96% for O2+ and 92 to 94% for AMB. There was no significant difference in training SpO~2~% between groups over the eight-week training intervention. Fig. 3Group mean ± SD for work-interval duration during week one (gray bars) and week eight (black bars) for the O2+ and AMB groups. \* *P* \< 0.05 compared to week one value within group; † *P* \< 0.05 compared to increase for AMB Table 5Progression in high-intensity work-interval duration for a representative subject from each group during the eight-week training interventionSESSION \#O2 + (s)AMB (s)110291020211579603115790041200120051350972615001044715001620816201800916881800101688192911168819291217741929131800192914180012881518001714

Discussion {#Sec19}
==========

The main original finding from this investigation is that an eight-week HIIT training program comprising 16 training sessions for individuals with CF shortened the V̇O~2~ MRT during constant-work-rate cycling at 30% of the participant's peak work rate and lengthened the time to limit of tolerance during constant-work-rate cycling at 70%. These findings support our experimental hypotheses and are consistent with the contention that HIIT provides a potent training stimulus that can improve the 'functional capacity' of individuals with CF. We also found that the enhanced ability to perform HIIT afforded by O~2~ supplementation did not bring about a significant change in either of these effects. Although the potential for a type II error due to our limited sample size cannot be discounted (see study limitations below), the observation that an intervention that markedly increased the volume of exercise that these individuals were able to perform at the same intensity did not result in a greater training effect is consistent with the contention that the stimulus provided by HIIT is related to intensity and not volume \[[@CR37]\].

In the present study, we had individuals with CF complete an eight-week training intervention comprising cycling bouts performed with 'work intervals' at work rates above the maximal sustainable pace interspersed with active recovery intervals of low-intensity cycling. High-intensity interval training of this type has long been a staple of athletic training \[[@CR38]\]; however, in recent years, the efficacy and safety of HIIT for populations with cardiopulmonary pathologies have been explored and results have been promising \[[@CR39], [@CR40]\]. Consistent with prior observations, we found HIIT to be a safe, effective exercise strategy for individuals with CF. Specifically, with respect to the former, no adverse events were observed and with respect to the latter, HIIT shortened the V̇O~2~ MRT, which means that it accelerated V̇O~2~ kinetics. In all likelihood, this has important functional implications during activities of daily living for these individuals \[[@CR13]\]. A faster V̇O~2~ response to a given increase in physical activity results in less metabolic perturbation (e.g., phosphocreatine degradation and blood \[lactate\] accumulation); hence, the cumulative positive effect of accelerated V̇O~2~ kinetics over the many submaximal transitions that comprise daily life has the potential to be considerable \[[@CR14]\]. We also found a decrease in blood \[lactate\] accumulation and ventilation along with an increase in time to exhaustion during high-intensity exercise due to HIIT. While time to limit of tolerance during 'unsustainable' constant-work-rate exercise as a viable indicator of clinical significance can be questioned, this might represent additional evidence of the functional benefit that occurs due to HIIT. For example, in an official statement from the European Respiratory Society that reviewed the use of exercise testing in the evaluation of interventional efficacy, Puente-Maestu et al. state that time to exhaustion derived from a CWR is a particularly sensitive index of interventional change in respiratory diseases \[[@CR19]\]. Previous research suggests that repeat-sprint training (SIT; i.e., HIIT performed with work intervals comprising all-out exercise) accelerates V̇O~2~ kinetics and improves high-intensity exercise tolerance in healthy subjects \[[@CR41]\]; hence, our findings provide preliminary evidence that this observation might be extended to HIIT for the CF population.

The safety and efficacy of HIIT for individuals with CF has been established previously \[[@CR28], [@CR42]\]; however, with respect to the latter, outcome measures to determine HIIT's beneficial effect were derived from maximal cardiopulmonary exercise testing (e.g., peak rates of V̇O~2~ and/or V̇~E~, ventilatory threshold) and did not include any that were related to V̇O~2~ kinetics. While this means of assessment represents the accepted way for testing 'functional capacity,' the degree to which an incremental test to limit of tolerance accurately reflects the capacity to meet the energetic demands of everyday life has been questioned \[[@CR13]\]. Conversely, working at a submaximal rate of work (albeit not constant) provides a physical challenge more like that which is encountered on a daily basis. It has also been shown that CWR testing is better suited for detecting and quantifying changes in exercise capacity in COPD subjects \[[@CR43]\]. Collectively, this implies that determining the beneficial effects of exercise training for individuals with CF should include an assessment like the CWR kinetics testing we employed. Interestingly, we also used incremental exercise to assess training-induced changes and found no effect on any of the parameters that we measured. The reason for this lack of coherence with previous research is unclear, but might represent differential effects secondary to disease progression of our CF subjects and/or the specific type of HIIT protocol that we employed.

It is well established that individuals with CF possess slower V̇O~2~ kinetics compared to healthy counterparts \[[@CR13], [@CR18], [@CR26]\]. Generally speaking, V̇O~2~ kinetics can be rate limited by an upstream O~2~-transport limitation or a 'metabolic inertia' within the active muscle mitochondria \[[@CR14]\] (i.e., a central or peripheral limitation, respectively). Although not without controversy \[[@CR44]\], in healthy subjects during 'normal' exercise (e.g., walking, running, upright cycling), the preponderance of evidence suggests that V̇O~2~ kinetics is rate limited by metabolic inertia \[[@CR14]\]. However, a reduced capacity for O~2~ delivery due to pathological changes, aging and/or environmental/experimental conditions (e.g., supine cycling, hypoxic inspiration) has the potential to shift the locus of limitation past a 'tipping point' thereby establishing O~2~ availability as the rate-limiting step \[[@CR14]\]. It is intuitive to suggest that the pulmonary complications of CF would shift the site of limitation of V̇O~2~ kinetics past the tipping point into the O~2~-delivery-dependent zone, thereby explaining the slowed V̇O~2~ kinetics that has been observed for these individuals. However, Kusenbach et al. found that O~2~ supplementation (40%) that normalized O~2~ saturation in subjects with CF did not alter either V̇O~2~ kinetics or RER during cycling at submaximal work rates \[[@CR25]\]. Furthermore, Saynor et al. found preserved cardiac function and central O~2~ delivery for children and adolescents with mild-to-moderate CF despite markedly slower V̇O~2~ kinetics during very-heavy cycling with the arterio-venous O~2~-content difference they measured during the initial 60 s of exercise significantly correlated with the V̇O~2~ MRT and phase II time constant (i.e., indices which indicate the rapidity of the V̇O~2~ response) \[[@CR13]\]. Collectively, these findings suggest a limitation based on the ability of muscle mitochondria to extract/utilise the O~2~ that is delivered. Conversely, Hebestreit et al. observed an inverse relationship between SpO~2~ and the phase II V̇O~2~ time constant for subjects with CF during semi-supine cycling, which is consistent with rate limitation rooted in insufficient O~2~ delivery \[[@CR26]\]. The reason(s) for these disparate findings is/are unclear, but might be related to the mode and/or intensity of the exercise challenge and/or the degree of disease progression for the subjects with CF. Although well beyond the scope of our investigation, it is interesting to note that the HIIT approach we employed which accelerated V̇O~2~ kinetics in individuals with CF did not increase V̇O~2peak~. Importantly, we did not assess central and peripheral function independently in this investigation; however, being that the maximal V̇O~2~ response would presumably be rate limited by central factors in these subjects \[[@CR20]\] and given the propensity for HIIT to be particularly suited for inducing peripheral adaptations \[[@CR45]\], our findings appear to support the contention that a peripherally-based factor was rate limiting V̇O~2~ kinetics in our CF subjects at least during the lower-intensity exercise challenge for which HIIT shortened the MRT. Moreover, during the higher-intensity exercise challenge, the \~ 90% increase in time to exhaustion elicited by HIIT was achieved despite unchanged SpO~2~ at the pre-training time to exhaustion. This finding might also be consistent with a HIIT-induced improvement in peripheral function because time to limit of tolerance was extended post training despite unchanged pathology-related pulmonary restrictions that have the potential to influence the limit of exercise tolerance for these individuals. However, more research is required to confirm this speculation using assessments that allow for differentiation of the two general potential locations of limitation/adaptation of oxidative function (i.e., central and peripheral).

In the present study, in addition to the effect of HIIT per se, we divided our cohort of nine CF subjects into a group that performed HIIT with O~2~ supplementation and another that did so while breathing ambient air. Our objectives were two-fold: first, to determine whether O~2~ supplementation would allow for longer high-intensity work intervals during HIIT; and second, to determine whether advantages afforded by O~2~ supplementation during HIIT would result in a greater training effect. We found that the increase in work-interval duration that occurred over the course of the eight-week HIIT intervention was significantly greater with O~2~ supplementation (see Fig. [2](#Fig2){ref-type="fig"}), which means that individuals with CF were able to perform longer periods of challenging work when they were breathing the hyperoxic inspirate. This is consistent with previous findings (see below); however, due to administrative challenges, we did not blind our test administrators to gas inspirate in the present study. Consequently, we cannot discount the possibility that administrator bias affected the decision making regarding the progressive increase in work-interval duration that was present over the course of the study. Importantly, these decisions were made based on the participant's perceived responses (a subjective variable) which means that a bias might have affected the results. In addition to prior research (see below), future research should be designed to confirm that hyperoxic gas inspirate provided by administrators who are blinded to the intervention they are supplying improves the ability to progress high-intensity interval duration over the course of a study like the present one.

The increased ability to sustain high-intensity work intervals that we observed for individuals with CF during HIIT with hyperoxic gas inspiration is consistent with previous findings. For example, McKone et al. had subjects with moderate-to-severe CF perform submaximal cycling at 80% of their maximal work rate to the limit of tolerance both with and without O~2~ supplementation (39%) and found that the same end-exercise V̇O~2~, V̇~E~ and HR were achieved after an \~ 26% increase in cycling duration when subjects breathed the hyperoxic mixture \[[@CR31]\]. This enhanced exercise tolerance occurred in association with an increase in arterial O~2~ saturation (\~ 96% compared to \~ 86% in the control condition) with a significant relationship observed between the increase in exercise time and the amount of O~2~ desaturation during the control test \[[@CR31]\]. This suggests that the ability for O~2~ supplementation to improve exercise tolerance depends on the degree of pathological compromise that is present for the individual. The reason(s) that O~2~ supplementation improves exercise tolerance for individuals with CF is unclear, but likely involves prolongation of the time taken for the individual to reach their maximum ventilatory capacity thereby reducing the sensation of dyspnea associated with the exercise challenge \[[@CR31]\]. Specifically, maintenance of higher arterial PO~2~ during exercise results in both direct and indirect chemoreceptor inhibition, which reduces the ventilatory requirement \[[@CR46]\]. Maintaining higher arterial saturation during exercise also has the potential to provide advantages at the periphery by allowing the same rate of mitochondrial respiration to be achieved with less perturbation of cellular phosphorylation state and redox potential. This would loosen a limitation to exercise tolerance that was present at the periphery.

Despite the marked amplification of the increase in work-interval duration that occurred over the course of our study, CF subjects that benefited from hyperoxic inspiration did not experience a greater reduction in the V̇O~2~ MRT (CWR~30~) or increase in time to exercise tolerance/decrease in blood \[lactate\] response (CWR~70~) compared to subjects inspiring ambient air. While this appears counterintuitive, a possible explanation is that the stimulus provided by HIIT is exclusively based on the overload provided by intensity; hence, it cannot be enhanced by an increase in volume. Support for this contention comes from a recent report that for individuals with metabolic syndrome, HIIT was equally effective for reducing disease severity when it was performed for 50 min per week compared to 114 \[[@CR37]\]. Furthermore, for healthy individuals, a 10-week HIIT program (three sessions per week) improved V̇O~2max~ and decreased the O~2~ cost of submaximal work to a similar extent regardless of whether it comprised one 4-min work interval at 90% of maximal heart rate or four \[[@CR47]\]. Indeed, it is this intensity dependence that is responsible for the time efficiency that is often touted as the major benefit of HIIT. Consequently, our findings cohere with this notion and suggest that the volume increase afforded by O~2~ supplementation during HIIT is not necessary to derive the benefits we observed for CF subjects from this form of training.

In addition to our finding of an improved capacity to transition to work intensities commensurate with those that occur during daily life, our findings might be important for individuals with CF because they imply that HIIT improves function irrespective of exercise volume and/or an intervention like supplemental O~2~ that might not be easily accessible to all individuals. However, with respect to the latter, it is important to note that our methodology (i.e., using supplemental O~2~ to increase the duration of work intervals with work rate held constant) does not allow us to rule out the possibility that O~2~ supplementation might be of benefit if intensity is allowed to fluctuate. For example, it is possible that an increase in work-interval work rate for the same duration of exercise might have resulted in a greater training effect. Alternatively, if O~2~ supplementation allows for an increased work rate during HIIT work intervals, individuals with CF might achieve the same training effect with a reduced exercise time commitment (for example, a 30-min HIIT session instead of 45). This would increase the likelihood of program adherence for a subject population at high risk for dropout \[[@CR48]\]. Future research should explore these potential benefits of O~2~ supplementation with HIIT for individuals with CF.

There were a number of unexpected findings in our study. For example, a main effect for time indicated that body-fat percentage was increased in the entire cohort post compared to pre training. This might reflect the fact that we did not control energetic intake during the eight-week intervention. Participants were, therefore, able to voluntarily alter their 'normal' diet if they so desired and it appears that they did so by increasing energetic intake to a greater extent compared to the additional energetic outlay that was required for the training that was introduced into their daily regime. The end result was an energetic surplus that was stored as body fat. We also observed a significant main effect for time for measurement of SpO~2~ during incremental exercise to limit of tolerance which indicated greater O~2~ desaturation in the entire cohort post compared to pre training. This might be a function of the 'trend' for a main effect for peak work rate post compared to pre training; that is, participants were able to reach a higher absolute rate of work which required greater use of the O~2~ content of their blood. Although highly speculative (see above), this is consistent with our suggestion that the changes in function that were present post compared to pre training which would have allowed for this greater peak rate of work were located predominantly at the periphery (i.e. an increase in the ability to use O~2~ that is being delivered as opposed to an increase in the ability to deliver it).

Our study is not without significant limitations. In addition to the one regarding administrator bias (see above), a major one is the small sample size which increases the likelihood of a type II error. Consequently, this might explain why we found no effect of HIIT on the parameters assessed during incremental exercise and/or no effect of O~2~ supplementation on the benefits derived from HIIT during CWR exercise. The small sample size also had the potential to amplify the influence of differences that might have been present between participants prior to initiation of training that might have affected their response to the intervention and/or our statistical findings. We are also limited in our ability to provide greater insight into our observations regarding V̇O~2~ kinetics because we did not employ the more advanced modelling procedures that are necessary to isolate the various phases of the V̇O~2~ response. We chose the more rudimentary approach (i.e., fitting a single exponential curve to the entire V̇O~2~ response) because of concerns regarding the signal-to-noise ratio that is attainable when only one exercise transition is performed \[[@CR49]\]. Future research exploring the influence of HIIT on V̇O~2~ kinetics and exercise tolerance should, therefore, be designed with larger sample sizes and pre/post CWR testing comprising multiple repetitions of the same exercise transition. Hopefully, the findings from our study will lead to research of this kind.

Conclusions {#Sec20}
===========

In summary, we have shown that an eight-week training intervention comprising two HIIT sessions per week resulted in a reduced V̇O~2~ MRT during lower-intensity CWR cycling and increased time to exhaustion during higher-intensity CWR cycling for individuals with CF. We have also shown that despite a markedly greater increase in work-interval duration over the course of the training intervention, the training effect with compared to without O~2~ supplementation was similar. Collectively, these findings offer preliminary evidence that HIIT provides a time-efficient intensity-driven training stimulus that is appropriate for improving functional capacity in individuals with CF.

\[lactate\]

:   Blood lactate concentration

A

:   Amplitude

AMB

:   Group that inspired ambient air during training

BR

:   Breathing rate

CF

:   Cystic fibrosis

CO~2~

:   Carbon dioxide

CWR

:   Constant-work-rate exercise

DLCO

:   Diffusing capacity for carbon monoxide

FEV~1~

:   Forced expiratory volume in 1 s

FVC

:   Forced vital capacity

HIF1α

:   Hypoxia-inducible factor 1-alpha

HIIT

:   High-intensity interval training

HR

:   Heart rate

MRT

:   Mean response time

MVV

:   Maximal voluntary ventilation

O2+

:   Group that inspired supplemental oxygen during training

O~2~

:   Oxygen

RER

:   Respiratory exchange ratio

RPE

:   Rating of perceived exertion

SpO~2~

:   Peripheral capillary O~2~ saturation

V̇~E~

:   Rate of minute ventilation

V̇~Epeak~

:   Peak rate of minute ventilation

V̇O~2~

:   Rate of oxygen uptake

V̇O~2-base~

:   Baseline rate of oxygen uptake

V̇O~2peak~

:   Peak rate of oxygen uptake

V~T~

:   Tidal volume

WR~peak~

:   Peak rate of work on incremental cycling test

∆V̇O~2\ (6-3)~

:   change in V̇O~2~ from minute 3 to 6
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